Go Pro
→ SpaceX pays a 10X launch penalty (From Freedom Financial) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$55.70
-1.6%		$57.59
$11.40
▼
$72.36
$1.68B0.71426,523 shs295,682 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.18
-1.4%		$2.22
$1.61
▼
$6.88
$397.99M0.952.48 million shs2.61 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.85
-3.3%		$8.63
$6.20
▼
$11.97
$1.68B2.455.13 million shs4.44 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$22.01
-17.7%		$28.70
$11.70
▼
$40.65
$1.60B0.73496,316 shs6.07 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.59%-0.25%+0.41%+2.69%+151.69%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-1.36%-10.29%-1.80%+8.46%-37.36%
Novavax, Inc. stock logo
NVAX
Novavax
-3.34%-4.55%+24.84%+9.08%+23.74%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-17.66%-12.42%-16.15%-13.92%+86.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$55.70
-1.6%		$57.59
$11.40
▼
$72.36
$1.68B0.71426,523 shs295,682 shs
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$2.18
-1.4%		$2.22
$1.61
▼
$6.88
$397.99M0.952.48 million shs2.61 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$9.85
-3.3%		$8.63
$6.20
▼
$11.97
$1.68B2.455.13 million shs4.44 million shs
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
$22.01
-17.7%		$28.70
$11.70
▼
$40.65
$1.60B0.73496,316 shs6.07 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-1.59%-0.25%+0.41%+2.69%+151.69%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-1.36%-10.29%-1.80%+8.46%-37.36%
Novavax, Inc. stock logo
NVAX
Novavax
-3.34%-4.55%+24.84%+9.08%+23.74%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-17.66%-12.42%-16.15%-13.92%+86.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
2.67
Moderate Buy$79.8543.35% Upside
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
2.88
Moderate Buy$11.77439.87% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.33
Hold$14.0042.13% Upside
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2.79
Moderate Buy$48.22119.09% Upside

Current Analyst Ratings Breakdown

Latest CMPX, TYRA, NVAX, and ANAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$56.00
9/4/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$45.00
8/31/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$78.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$75.00 ➝ $70.00
8/25/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Scotiabank logo
Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold$70.00
8/24/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$95.00
8/7/2026
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/7/2026
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$4.00 ➝ $6.00
8/6/2026
Novavax, Inc. stock logo
NVAX
Novavax
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/5/2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$42.00
8/4/2026
Novavax, Inc. stock logo
NVAX
Novavax
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
$234.60M7.03N/AN/A$1.34 per share41.57
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
$850K461.88N/AN/A$1.11 per share1.96
Novavax, Inc. stock logo
NVAX
Novavax
$1.12B1.45$3.40 per share2.90($0.79) per share-12.47
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/A$4.86 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
-$13.23M-$1.08N/A18.75N/A-11.53%N/A-7.75%11/10/2026 (Estimated)
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$66.49M-$0.40N/AN/AN/AN/A-38.71%-34.72%11/4/2026 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
$440.30M-$1.52N/AN/AN/A-59.87%-14.82%-13.35%11/5/2026 (Estimated)
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$119.95M-$2.40N/AN/AN/AN/A-46.39%-43.07%11/4/2026 (Estimated)

Latest CMPX, TYRA, NVAX, and ANAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
-$0.1107-$0.13-$0.0193-$0.13($0.60) millionN/A
8/6/2026Q2 2026
Novavax, Inc. stock logo
NVAX
Novavax
-$0.3798-$0.32+$0.0598-$0.32$52.51 million$56.70 million
8/4/2026Q2 2026
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
-$0.6499-$0.69-$0.0401-$0.69N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/AN/AN/AN/AN/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
7.58
7.58
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
N/A
11.22
11.22
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.33
2.30
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
N/A
14.90
14.91

Institutional Ownership

CompanyInstitutional Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
N/A
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
68.43%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
84.14%

Insider Ownership

CompanyInsider Ownership
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
31.50%
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
18.70%
Novavax, Inc. stock logo
NVAX
Novavax
1.60%
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
12.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
AnaptysBio, Inc. stock logo
ANAB
AnaptysBio
10029.61 million20.28 millionOptionable
Compass Therapeutics, Inc. stock logo
CMPX
Compass Therapeutics
20180.09 million146.41 millionNot Optionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990164.95 million162.31 millionOptionable
Tyra Biosciences, Inc. stock logo
TYRA
Tyra Biosciences
2059.68 million52.22 millionOptionable

Recent News About These Companies

Balversa reversa? Tyra’s bladder cancer drug hits in phase II
 |  bioworld.comB
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data
September 9 at 5:51 PM  |  msn.comhttps://www.msn.com/en-us/news/other/tyra-biosciences-shares-plunge-30-after-phase-2-dabogratinib-data/ar-AA2bT0vX
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines
September 9 at 5:51 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4944515-tyra-biosciences-tanks-ir-nmibc-data-disappoints-firmly-on-sidelines
Tyra disappoints investors with bladder cancer data
September 9 at 5:51 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tyra-disappoints-investors-bladder-cancer-154600125.html
Why Is Tyra Biosciences Stock Sinking Wednesday?
September 9 at 1:00 PM  |  benzinga.comhttps://www.benzinga.com/markets/biotech/26/09/61693811/why-is-tyra-biosciences-stock-sinking-wednesday
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock
September 9 at 12:50 PM  |  fiercebiotech.comF
Tyra Biosciences Stock Plunges 22% Despite Positive Bladder Cancer Data
September 9 at 12:50 PM  |  rttnews.comhttps://www.rttnews.com/3689657/tyra-biosciences-stock-plunges-22-despite-positive-bladder-cancer-data.aspx
Tyra Biosciences (TYRA) Stock Drops 22% After Bladder Cancer Drug Data Misses the Bar
September 9 at 12:50 PM  |  coincentral.comC
Tyra Biosciences Shares Sink After Bladder-Cancer Treatment Causes Adverse Events in Some Patients During Clinical Trial
September 9 at 12:50 PM  |  marketwatch.comhttps://www.marketwatch.com/story/tyra-biosciences-shares-sink-after-bladder-cancer-treatment-causes-adverse-events-in-some-patients-during-clinical-trial-82e13966
Tyra drops after mid-stage trial data for lead asset in bladder cancer
September 9 at 12:50 PM  |  msn.comhttps://www.msn.com/en-us/money/general/tyra-drops-after-mid-stage-trial-data-for-lead-asset-in-bladder-cancer/ar-AA2bSfYL
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Down - Should You Sell?
September 9 at 11:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tyra-biosciences-nasdaq-tyra-shares-gap-down-should-you-sell-2026-09-09/
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
September 9 at 10:44 AM  |  barrons.comhttps://www.barrons.com/articles/tyra-biosciences-stock-bladder-cancer-pill-b78ad95c
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib
September 9 at 7:49 AM  |  markets.ft.comhttps://markets.ft.com/data/announce/detail?dockey=600-202609090700PR_NEWS_USPRX____LA42613-1
Tyra Biosciences to Present at the Cantor Global Healthcare Conference
September 8 at 4:05 PM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-the-cantor-global-healthcare-conference-302872416.html
103,720 Shares in Tyra Biosciences, Inc. $TYRA Bought by Bank of New York Mellon Corp
September 7 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-103720-shares-in-tyra-biosciences-inc-tyra-bought-by-bank-of-new-york-mellon-corp-2026-09-07/
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts
September 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4943429-tyra-biosciences-hold-ir-nmibc-data-september-9-2026-caution-ahead-2027-readouts
HC Wainwright Reaffirms Buy Rating for Tyra Biosciences (NASDAQ:TYRA)
September 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31005965
Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug
September 4, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/tyra-bio-rises-on-upcoming-mid-stage-trial-readout-for-bladder-cancer-drug/ar-AA2bzRVx
TYRA Stock Heads For Best Day In Nearly 10 Months — Sets Date For Key Phase 2 Bladder Cancer Drug Readout
September 4, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/tyra-stock-heads-for-best-day-in-nearly-10-months-sets-date-for-key-phase-2-bladder-cancer-drug-readout/ar-AA2bAUyu
Tyra Biosciences (NASDAQ:TYRA) Given "Buy" Rating at HC Wainwright
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-tyra-biosciences-nasdaq-tyra-given-buy-rating-at-hc-wainwright-2026-09-04/
Tyra Biosciences (NASDAQ:TYRA) Stock Price Up 6.2% - Still a Buy?
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-tyra-biosciences-nasdaq-tyra-stock-price-up-62-still-a-buy-2026-09-04/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AnaptysBio stock logo

AnaptysBio NASDAQ:ANAB

$55.70 -0.90 (-1.59%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$55.60 -0.10 (-0.18%)
As of 09/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Compass Therapeutics stock logo

Compass Therapeutics NASDAQ:CMPX

$2.18 -0.03 (-1.36%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$2.19 +0.01 (+0.69%)
As of 09/9/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$9.85 -0.34 (-3.34%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$9.83 -0.02 (-0.21%)
As of 09/9/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Tyra Biosciences stock logo

Tyra Biosciences NASDAQ:TYRA

$22.01 -4.72 (-17.66%)
Closing price 09/9/2026 04:00 PM Eastern
Extended Trading
$22.04 +0.03 (+0.14%)
As of 09/9/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas